Inhibrx Biosciences, Inc. INBX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $25.22M-31.6% | $25.35M-24.0% | $28.54M-26.6% | $22.27M-67.1% | $36.88M-42.2% | ||
| $5.71M-5.2% | $5.57M-66.5% | $5.28M-33.2% | $6.42M-93.1% | $6.02M-39.6% | ||
| $30.93M-27.9% | $30.92M-38.2% | $33.81M-27.7% | $28.69M-82.2% | $42.9M-41.9% | ||
| $30.93M-27.9% | $30.92M-38.2% | $33.81M-27.7% | $28.69M-82.2% | $42.9M-41.9% | ||
| -$30.93M+27.9% | -$30.92M+38.1% | -$33.81M+27.7% | -$27.39M+83.0% | -$42.9M+41.9% | ||
| $3.51M+30.5% | $3.19M— | $3.18M— | $3.14M-41.4% | $2.69M-66.9% | ||
| -$2.51M-513% | -$1.91M-193% | -$1.44M-149% | -$1.26M-100% | -$410K+91.6% | ||
| -$33.44M+22.8% | -$32.83M— | -$35.26M+19.6% | -$28.65M-102% | -$43.31M+45.0% | ||
| $0— | $0— | $0— | $2K0.0% | $0— | ||
| -$33.44M+22.8% | -$32.83M— | -$35.26M+19.6% | -$28.65M-102% | -$43.31M+45.0% | ||
| -$2.15+23.2% | -$2.11— | -$2.28+19.7% | -$1.85-101% | -$2.80+51.5% | ||
| -$2.15+23.2% | -$2.11— | -$2.28+19.7% | -$1.85-101% | -$2.80+51.5% | ||
| 15.6M+0.8% | 15.5M+3.4% | 15.5M+0.1% | 15.5M+4.5% | 15.5M+13.4% | ||
| 15.6M+0.8% | 15.5M+4.6% | 15.5M+0.1% | 15.5M+5.8% | 15.5M+13.4% | ||
| —— | $1.89M-31.0% | $1.89M-31.0% | $1.89M-31.0% | $1.89M-31.0% | ||
| $1.01M-56.8% | —— | $1.78M-38.3% | $2.12M-22.5% | $2.33M-29.5% | ||
| -$12K+76.0% | -$39K-165% | -$46K-212% | -$246K-845% | -$50K+15.3% | ||
| -$30.93M+27.9% | -$30.92M+38.1% | -$33.81M+27.7% | -$27.39M+83.0% | -$42.9M+41.9% | ||
| -$30.39M+28.0% | -$30.36M+38.3% | -$33.23M+27.8% | -$26.73M+83.3% | -$42.23M+42.5% | ||
| -$30.39M+28.0% | -$30.36M+38.3% | -$33.23M+27.8% | -$26.73M+83.3% | -$42.23M+42.5% | ||
| -$30.93M+27.9% | -$30.92M+38.1% | -$33.81M+27.7% | -$27.39M+83.0% | -$42.9M+41.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Inhibrx Biosciences, Inc.'s revenue?
- Inhibrx Biosciences, Inc. (INBX) generated $1.3M in revenue over the trailing twelve months, up 550.0% year over year.
- Is Inhibrx Biosciences, Inc. profitable?
- Inhibrx Biosciences, Inc. is not currently profitable: it reported a net loss of $130.2M over the trailing twelve months, a -10773.5% net margin.
- What is Inhibrx Biosciences, Inc.'s earnings per share?
- Inhibrx Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-8.39.
- Where does Inhibrx Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
